³ÉÈË¿ìÊÖ

The information requested on the amount spent on hyperthermic intraperitoneal chemotherapy is not centrally held.

I refer the member to the answer to question S6W-05641 on 25 January 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at /chamber-and-committees/written-questions-and-answers

Hyperthermic intraperitoneal chemotherapy (HIPEC) treatment is available in Scotland for those who would clinically benefit from it.

The information requested on the cancellation and postponement of hyperthermic intraperitoneal chemotherapy is not centrally held.

Organisations delivering services are responsible for implementing standards at a local level, and local quality frameworks and procedures will assist them in monitoring progress.

We are committed to exploring national governance arrangements as a part of the Independent Review of Audiology Services announced on 21 January 2022. This will include reviewing opportunities to improve data collection and a national peer review mechanism for monitoring progress in implementation of these standards across Scotland.

The information requested on how many people have been treated using hyperthermic intraperitoneal chemotherapy is not centrally held.

34 people were referred to England in 2017-18, 28 in 2018-19, 25 in 2019-20, 20 in 2020-21 and 13 people so far in 2021-22.

NHS Lothian have, as part of their action plan agreed with the Scottish Public Services Ombudsman, the British Academy of Audiology and the Scottish Government, contacted 92 children identified in the review as being of clinical concern and requiring possible retesting.

The Board continues to undertake work to review children known to the service who have risk factors for hearing loss and, based on the outcome of each review, recall children where appropriate in line with national guidance.

Impact Assessments have been part of the decision making process in our use of emergency Covid-19 powers. Policy continues to be developed with regard to the need to protect human rights, equality considerations, the impact on business and the particular needs of island communities. Appropriate impact assessments are carried out and reported to the Scottish Parliament.

All decisions made in the development of measures under the Covid-19 emergency powers have included careful assessment of the necessity and potential impacts of the powers and their compatibility with the Convention rights set out in the Human Rights Act 1998.

Appropriate impact assessments are carried out as part of this process and are reported to the Scottish Parliament.

Regulations made using Covid-19 legislation must be reviewed at least every 21 days by Scottish Ministers. This review process ensures that the measures they provide continue to be necessary and proportionate.

Any new or revised regulations are set out to the Scottish Parliament in plenary and are considered by the Parliament's Delegated Powers and Law Reform Committee and the Covid-19 Committee Recovery Committee.

Regulations made under Covid-19 legislation are considered through the Four Harms approach which draws on evidence and analysis to assess both current and future direct and indirect health impacts and the social and economic impacts of the pandemic and of proposed regulations. This approach is underpinned by Scotland’s Strategic Framework which sets out our approach to managing the pandemic.

Scottish Ministers also produce a report to Parliament every two months with regard to the status and operation of the Scottish and UK Coronavirus Acts – confirming that they have undertaken a review of whether the provisions continue to be necessary and proportionate.